Trial Profile

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epcoritamab (Primary) ; Rituximab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Doxorubicin; Prednisolone; Prednisone; Vincristine
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
Focus Registrational; Therapeutic Use
Acronyms EPCORE DLBCL-2
Sponsors AbbVie Germany; Genmab

23 Jan 2025 Status changed from recruiting to active, no longer recruiting.
04 Dec 2024 Planned End Date changed from 30 Dec 2029 to 1 Dec 2029.
04 Dec 2024 Planned primary completion date changed from 24 Sep 2028 to 1 Jun 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com